


PARP-1-IN-1

Cat. No.:	HY-144642
CAS No.:	2763840-83-9
Molecular Formula:	C ₂₃ H ₂₅ FN ₄ O
Molecular Weight:	392.47
Target:	PARP
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PARP-1-IN-1 is a high selective and orally active PARP-1 inhibitor (IC ₅₀ =0.96 nM). PARP-1-IN-1 has well tolerance and remarkable single dose activity in the MDA-MB-436 xenotransplantation model ^[1] .								
In Vitro	<p>PARP-1-IN-1 (compound Y49) (48 hours) has effective inhibition on different cancer cells (IC₅₀s of 9.64, 123.5 106.3 μM for MX-1, MCF7 and A548 cells, respectively)^[1].</p> <p>PARP-1-IN-1 (2.5-10 μM, 48 hours) successfully inhibits the activity of PARP-1 and reduces the production of PAR in A549 cells, which is dose-dependent to some extent^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>A549 cells</td> </tr> <tr> <td>Concentration:</td> <td>2.5 μM, 5 μM and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48h</td> </tr> <tr> <td>Result:</td> <td>Inhibited the activity of PARP-1 successfully and reduced the production of PAR in cancer cells. PARP-1-IN-1 was dose-dependent to some extent.</td> </tr> </table>	Cell Line:	A549 cells	Concentration:	2.5 μM, 5 μM and 10 μM	Incubation Time:	48h	Result:	Inhibited the activity of PARP-1 successfully and reduced the production of PAR in cancer cells. PARP-1-IN-1 was dose-dependent to some extent.
Cell Line:	A549 cells								
Concentration:	2.5 μM, 5 μM and 10 μM								
Incubation Time:	48h								
Result:	Inhibited the activity of PARP-1 successfully and reduced the production of PAR in cancer cells. PARP-1-IN-1 was dose-dependent to some extent.								
In Vivo	<p>PARP-1-IN-1 (compound Y49) (50 mg/kg/day; p.o.; daily for 18 days) inhibits the growth of MDA-MB-436 tumor in BALB/c nude mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female athymic BALB/c nude mice (inoculated MDA-MB-436 cells)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>p.o., daily for 18 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited the growth of MDA-MB-436 tumor significantly, and no significant change in the body weight of PARP-1-IN-1 treated mice.</td> </tr> </table>	Animal Model:	Female athymic BALB/c nude mice (inoculated MDA-MB-436 cells) ^[1]	Dosage:	50 mg/kg	Administration:	p.o., daily for 18 days	Result:	Inhibited the growth of MDA-MB-436 tumor significantly, and no significant change in the body weight of PARP-1-IN-1 treated mice.
Animal Model:	Female athymic BALB/c nude mice (inoculated MDA-MB-436 cells) ^[1]								
Dosage:	50 mg/kg								
Administration:	p.o., daily for 18 days								
Result:	Inhibited the growth of MDA-MB-436 tumor significantly, and no significant change in the body weight of PARP-1-IN-1 treated mice.								

REFERENCES

[1]. Yu J, et al. Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2. Eur J Med Chem. 2022;227:113898.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA